tirzepatide and kidney disease Renal effects of GLP-1 receptor agonists in individuals with type 2 diabetes: seeds of a promising future | Endocrine Can tirzepatide be used to

Since osteoporosis and obesity are two diseases that affect a vast majority of postmenopausal women concomitantly, using a single drug that is Food and Drug Administration (FDA) approved for obesity to prevent and manage both osteoporosis and obesity could improve the quality of life and decrease the complications and medical costs that occur as a result of both diseases

GLP-1 activity has recently been implicated in increasing BAT thermogenesis, and a further exploration of this interaction may better explain the full physiologic effects of GLP-1 agonists as they contribute to weight loss [65]

Novielli C, Anelli GM, Lisso F, et al

talakulhat a rkmegelzs szemllete A tanulmny taln legfontosabb zenete nem az, hogy talltunk egy j rkellenes csodaszert, hanem az, hogy a daganatmegelzsrl alkotott kpnk alapveten vltozik

doi:10.3390/nu10111564 [PubMed] 79